High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma

Journal of Surgical Oncology

Volumn 106, Issue 4, 2012, Pages 386-392

  Park, Min Ho ^a   Lee, Ji Shin ^a   Yoon, Jung Han ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

breast carcinoma; CD8+ T cells; CX3CL1; dendritic cells; natural killer cells; prognosis

Indexed keywords

CD57 ANTIGEN; CD8 ANTIGEN; FRACTALKINE; T6 ANTIGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL COUNT; DENDRITIC CELL; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE MIGRATION; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, CD57; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINE CX3CL1; DENDRITIC CELLS; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PROGNOSIS;

EID: 84865143605     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23095     Document Type: Article

References (29)

1. Jung KW, Park S, Kong HJ, et al.: Cancer statistics in Korea: Incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25: 1113-1121.
2. Hudis CA:, Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4: S70-S75. (Pubitemid 38028832)
3. Radpour R, Barekati Z, Kohler C, et al.: New trends in molecular biomarker discovery for breast cancer. Genet Test Mol Biomarkers 2009; 13: 565-571.
4. Tan PH, Lota AS:, Interaction of current cancer treatments and the immune system: Implications for breast cancer therapeutics. Expert Opin Pharmacother 2008; 9: 2639-2660.
5. Wei S, Kryczek I, Zou L, et al.: Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells. Discov Med 2005; 5: 489-492.
6. Zitvogel L, Tesniere A, Kroemer G:, Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727. (Pubitemid 44453458)
7. Cruz I, Meijer CJ, Walboomers JM, et al.: Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas. Br J Cancer 1999; 81: 881-889. (Pubitemid 29504701)
8. Smyth MJ, Hayakawa Y, Takeda K, et al.: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861. (Pubitemid 37328903)
9. Hart DN:, Dendritic cell biology evolves into clinical application. Lancet 2005; 365: 102-104. (Pubitemid 40091791)
10. La Rocca G, Anzalone R, Bucchieri F, et al.: CD1a and antitumour immune response. Immunol Lett 2004; 95: 1-4. (Pubitemid 39119893)
11. Zlotnik A, Yoshie O:, Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127. (Pubitemid 30398626)
12. Soria G, Meshel T, Ben-Baruch A:, Chemokines in human breast tumor cells: Modifying their expression levels and determining their effects on the malignancy phenotype. Methods Enzymol 2009; 460: 3-16.
13. Imai T, Hieshima K, Haskell C, et al.: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-530. (Pubitemid 27508241)
14. Guo J, Zhang M, Wang B, et al.: Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003; 103: 212-220. (Pubitemid 35461513)
15. Lavergne E, CombadiÃre B, Bonduelle O, et al.: Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003; 63: 7468-7474. (Pubitemid 37413490)
16. Xin H, Kikuchi T, Andarini S, et al.: Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005; 35: 1371-1380. (Pubitemid 40691418)
17. Nukiwa M, Andarini S, Zaini J, et al.: Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 2006; 36: 1019-1027.
18. Ohta M, Tanaka F, Yamaguchi H, et al.: The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005; 26: 41-47.
19. Hyakudomi M, Matsubara T, Hyakudomi R, et al.: Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1775-1782.
20. Matsubara T, Ono T, Yamanoi A, et al.: Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 2007; 95: 241-249.
21. Menon AG, Janssen-van Rhijn CM, Morreau H, et al.: Immune system and prognosis in colorectal cancer: A detailed immunohistochemical analysis. Lab Invest 2004; 84: 493-501. (Pubitemid 41656477)
22. La Rocca G, Anzalone R, Corrao S, et al.: CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. Histopathology 2008; 52: 203-212.
23. Al-Shibli K, Al-Saad S, Donnem T, et al.: The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009; 55: 301-312.
24. Lv L, Pan K, Li XD, et al.: The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 2011; 6: e18219.
25. Mahmoud SM, Paish EC, Powe DG, et al.: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
26. Vgenopoulou S, Lazaris AC, Markopoulos C, et al.: Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. Breast 2003; 12: 172-178. (Pubitemid 36665514)
27. Matkowski R, Gisterek I, Halon A, et al.: The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 2009; 29: 2445-2451.
28. Andre F, Cabioglu N, Assi H, et al.: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006; 17: 945-951. (Pubitemid 43778984)
29. Hatori K, Nagai A, Heisel R, et al.: Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 2002; 69: 418-426. (Pubitemid 34809490)